Response to: Should we give long-term macrolide therapy for COPD?
- Correspondence to Dr Richard K Albert, Department of Medicine, Denver Health, 777 Bannock MC 4000, Denver, CO 80204-4507, USA;
- Received 24 June 2013
- Accepted 26 June 2013
- Published Online First 13 July 2013
The letter submitted by Crosbie and Woodhead1 pertaining to our study of azithromycin for prevention of acute chronic obstructive pulmonary disease (COPD) exacerbations2 contains a number of errors and misconceptions.
First, Crosbie and Woodhead stated that our study was not double-blind. The complete protocol (published as an on-line supplement to the manuscript) indicated that ‘This is a prospective, randomised, double-blind, placebo-controlled trial…’.1
Second, while Crosbie and Woodhead correctly note that …